Indivior Plc ( INDV ) stock plunged following the company’s fiscal year 2025 guidance that fell short of Street expectations.

Addiction and mental illnesses-focused Indivior ( INDV ) reported fourth-quarter sales of $298 million, up 2% year over year, beating the consensus of $259.3 million.

The London-based healthcare firm reported adjusted EPS of 32 cents, down from 43 a year ago, beating the consensus of 21 cents.

In the fourth quarter, adjusted operating profit remained unchanged at $66 million, while adjusted net income declined 33% year-over-year to $41 million.

Also Read: Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details

Sales of Sublocade, its newer long-acting treatment for opioid use disorder, increased 10% year over year to $194 million, and U.S. units dispensed were approximately 161,400, up 13%.

Suboxone Film revenue declined in the fourth quarter due to increased generic competitive activity, resulting in an average share of 15.2% versus 18.4% a year ago.

Sales of Perseris, its schizophrenia drug, fell 25% to $9 million. As previously announced, Perseris’ marketing and promotion have been discontinued.

In February, the FDA informed Indivior ( INDV ) that, following acceptance of the proposed label for Sublocade, there were no outstanding items for the company to address, but the final review of the label was delayed.

Guidance: Indivior ( INDV ) expects 2025 revenue of $955 million to $1.025 billion, versus a consensus of $1.09 billion, representing a 17% decline.

The company expects adjusted EBIT guidance of $185 million to $225 million. Sublocade sales are expected to reach $725 million to $765 million, down 1% year over year.

The guidance anticipates accelerated erosion in Suboxone sales, reflecting an increased generic competitive activity and the potential impact of a fifth buprenorphine/ naloxone sublingual film generic in the U.S. market.

Indivior ( INDV ) is cutting over $100 million in costs, of which approximately $50 million will be reinvested in Sublocade and the opioid use disorder-focused pipeline. Over $50 million will help protect adjusted operating profit.

Price Action: INDV stock is down 16.50% to $9.11 at the last check on Thursday.

Read Next:

Airbus Q4 Earnings: Revenue Surges 8%, Order Intake Value Declines And More